ACCESS-T1D: Florida relatives and autoimmune-risk screening
What this study tests
Active, not recruiting one-visit autoantibody screen in underserved children and adults in eight Florida counties who have a relative with T1D, another autoimmune disease, or suspected misdiagnosed T1D. Actual enrolment 115. It finds people at risk; it is not a treatment trial.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-08-12.
Most recent recorded citation date: 2026-08-12. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Age 2 and older, living in Orange, Seminole, Osceola, Lake, Volusia, Brevard, Polk, or Hillsborough County, Florida, and at elevated risk because of a first- or second-degree relative with T1D, another autoimmune disease, or another diabetes diagnosis suspected to be T1D (BMI 28 or lower, or insulin within three years of diagnosis). People already meeting stage 3 T1D criteria are excluded. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. Active, not recruiting; actual n=115; actual start 11 March 2024; estimated completion December 2026. Last registry update 12 August 2026. Orlando site.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Islet-autoantibody status on the single study visit
The full picture
ACCESS-T1D is a local relatives-and-autoimmune-risk screen, closer to other regional programmes than to a national population screen. A completed blood draw is not a published yield, and it does not change how teplizumab or any other delay therapy is ranked.
Sources
- [1]NCT06908057: ACCESS-T1D screening for underserved children and adults · Trial registry · 2026-08-12